Autopsy report · NCT04237649

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

“Business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 7 months before it stopped.
• 77 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Solid Tumors

Interventions

KAZ954; PDR001; NIR178; NZV930

Participants

77

Sites

13

Countries

Canada, Hong Kong, Italy, Japan, Singapore, Spain, Taiwan, United States

Trials that died the same way

• StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
  “Business Reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
  “for business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.